Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TML-6
- Development stage
- Phase 2
- Lead developer
- Merry Life Biomedical
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
TML-6 is a novel synthetic curcumin analog developed as an oral drug for the treatment of Alzheimer's disease. It was identified through screening of 12 compounds from Androscience using a platform based on six aging and Alzheimer's disease biomarkers by Professor Ih-Jen Su at Southern Taiwan University. TML-6 exhibits a multi-target mechanism of action, including inhibition of β-amyloid precursor protein synthesis and β-amyloid accumulation, upregulation of Apo E, suppression of NF-kB and mTOR pathways (autophagy activation), anti-inflammatory effects, and increased activity of the anti-oxidative Nrf2 gene. Preclinical studies in two animal models demonstrated its potential to improve or reverse early-stage Alzheimer's disease progression. TML-6 has high bioavailability due to its formulation and has completed preclinical toxicology and safety studies. As of 2024, it is entering Phase 1 clinical trials in the United States with plans for global Phase 2a trials[1][2][4][5][7].
- Other names
- tml-6tml6tml 6asc-6asc6asc 6
02
Targets
Aβ (Amyloid-beta peptides and aggregates)mTOR (Mammalian target of rapamycin kinase)NFE2L2 (Nuclear factor (erythroid-derived 2)-like 2)NF-κB
Beyond the preview
Go deeper on TML-6.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TML-6.